专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2011018480A1 COMPOSITION PHARMACEUTIQUE COMPRENANT UN ESTER DE DHA DESTINEE A ETRE ADMINISTREE PAR VOIE PARENTERALE 审中-公开
标题翻译：药物组合物，包括一个DHA ESTER被联合管理
公开(公告)号：WO2011018480A1
公开(公告)日：2011-02-17
申请号：PCT/EP2010/061701
申请日：2010-08-11
申请人： PIERRE FABRE MEDICAMENT , LEVERD, Elie , VAN HOOGEVEST, Peter , KUNG, Elsa , LEIGH, Mathew
发明人： LEVERD, Elie , VAN HOOGEVEST, Peter , KUNG, Elsa , LEIGH, Mathew
IPC分类号： A61K9/107 , A61K9/127 , A61K31/232 , A61K31/455 , A61K47/14 , A61K47/24
CPC分类号： A61K47/14 , A61K9/0019 , A61K9/1075 , A61K31/232 , A61K31/455
摘要： La présente invention cible une composition pharmaceutique destinée à être administrée par voie parentérale, comprenant des particules submicroniques d'ester de l'acide docosahexaenoïque, dispersées dans une phase aqueuse à l'aide d'un mélange d'au moins deux tensio-actifs choisis parmi a) au moins un ester d'acide gras polyoxyéthyléné et b) au moins un dérivé phospholipidique. La présente invention cible également le procédé de préparation de ladite composition pharmaceutique.
摘要翻译：本发明涉及一种药物组合物，其包括使用至少两种选自a）至少一种聚氧乙烯脂肪酸酯和b）之间的混合物在水相中分散二十二碳六烯酸的亚微米酯颗粒，至少一种磷脂衍生物。本发明还涉及制备所述药物组合物的方法。

2. 发明申请

WO2004037216A1 MICRODISPERSION AND METHOD OF PRODUCING SAME 审中-公开
标题翻译：微生物及其生产方法
公开(公告)号：WO2004037216A1
公开(公告)日：2004-05-06
申请号：PCT/EP2003/011936
申请日：2003-10-28
申请人： PHARES PHARMACEUTICAL RESEARCH N.V. , LEIGH, Mathew, Louis, Steven , LEIGH, Steve , VAN HOOGEVEST, Peter , KUNG, Elsa
发明人： LEIGH, Mathew, Louis, Steven , LEIGH, Steve , VAN HOOGEVEST, Peter , KUNG, Elsa
IPC分类号： A61K7/00
CPC分类号： A61K8/06 , A61K8/345 , A61K8/37 , A61K8/375 , A61K8/553 , A61K2800/21 , A61Q19/00 , A61Q19/08
摘要： The invention describes homogeneous microdispersions comprising at least one hydrogenated or partially hydrogenated membrane lipid with or without enzyme hydrolysis, dispersed in substantially non aqueous, non volatile hydrophilic medium with boiling point above 40°C. More preferably the compositions comprise a mixture of hydrogenated monoacyl and hydrogenated diacyl lipids and at least one oil. The phospholipid mixture is obtained by controlled enzyme hydrolysis of lecithin or a specific phospholipid, followed by hydrogenation. The compositions have improved rheology, physical and chemical properties, functionality and industrial applicability. The microdispersions are used as such in all types of applications and as functional components with active compounds in products, particularly for improving skin function and facilitating skin repair due to UV damage and aging, in cosmetics and other topical products.
摘要翻译：本发明描述了均匀的微分散体，其包含至少一种具有或不具有酶水解的氢化或部分氢化的膜脂质，分散在沸点高于40℃的基本上非水性的非挥发性亲水介质中。更优选地，组合物包含氢化单酰基和氢化二酰基脂质与至少一种油的混合物。磷脂混合物通过卵磷脂或特定磷脂的受控酶水解，然后氢化而获得。组合物具有改善的流变性，物理和化学性质，功能性和工业适用性。微分散体在所有类型的应用中都是这样使用的，并且作为在产品中具有活性化合物的功能组分，特别是用于改善皮肤功能并促进由于紫外线损伤和老化引起的皮肤修复，在化妆品和其它局部产品中。

3. 发明申请

WO2004075872A1 AMBIPHILIC POROUS MATRIX 审中-公开
标题翻译：辅助多孔矩阵
公开(公告)号：WO2004075872A1
公开(公告)日：2004-09-10
申请号：PCT/EP2004/001985
申请日：2004-02-27
申请人： PHARES PHARMACEUTICAL RESEARCH N.V. , LEIGH, Mathew, Louis, Steven , LEIGH, Steve , KUNG, Elsa , VAN HOOGEVEST, Peter
发明人： LEIGH, Mathew, Louis, Steven , LEIGH, Steve , KUNG, Elsa , VAN HOOGEVEST, Peter
IPC分类号： A61K7/48
CPC分类号： A61K8/0279 , A61K8/24 , A61K8/26 , A61K8/553 , A61K8/731 , A61K8/922 , A61K2800/56 , A61Q1/02 , A61Q1/06 , A61Q1/08 , A61Q1/10 , A61Q19/00
摘要： Compositions are described which are capable of forming external reservoirs comprising a polymeric matrix for adsorbing sebum in exchange for beneficial oils and transfer of hydrating components to the skin. The compositions may be lotions, creams, gels, pastes, lip sticks and water in oil systems. There is also described a method of preparing said lotions, creams, etc containing an ambiphilic powder mixture or complex comprising synthetic porous agglomerates, a lipophilic component, hydrophilic attractant/polymer, optionally biologically active compound and excipients.
摘要翻译：描述了能够形成外部储存器的组合物，其包含用于吸收皮脂的聚合物基质，以换取有益的油并将保湿组分转移至皮肤。组合物可以是乳液，乳膏，凝胶，糊剂，唇膏和油中的水。还描述了一种制备含有含有合成多孔团聚物，亲脂性成分，亲水性引诱剂/聚合物，任选的生物活性化合物和赋形剂的两性粉末混合物或复合物的所述洗剂，霜剂等的方法。

4. 发明申请

WO2010049499A1 FORMULATION FOR TREATMENT OF VAGINAL DRYNESS 审中-公开
标题翻译：用于治疗阴道干燥的配方
公开(公告)号：WO2010049499A1
公开(公告)日：2010-05-06
申请号：PCT/EP2009/064312
申请日：2009-10-29
申请人： MEDLITE AS , HANSEN, Ketil, Andre , FAGERLAND, Tore , AFSETH, John , LEIGH, Mathew , KUNG, Elsa , VAN HOOGEVEST, Peter
发明人： HANSEN, Ketil, Andre , FAGERLAND, Tore , AFSETH, John , LEIGH, Mathew , KUNG, Elsa , VAN HOOGEVEST, Peter
IPC分类号： A61K9/00 , A61K47/10 , A61K47/24 , A61K47/26 , A61K47/44 , A61K47/48 , A61P15/02
CPC分类号： A61K9/0034 , A61K47/10 , A61K47/14 , A61K47/26 , A61K47/44
摘要： The present invention is directed to a composition for treating vaginal dryness and lack of lubrication comprising: a poloxamer component; a phospholipid component; an optional oil component; and a non-aqueous carrier; wherein the composition is substantially anhydrous. In another aspect, the present invention is directed to a method of treating vaginal dryness comprising the step of administering to a patient suffering from vaginal dryness the above composition.
摘要翻译：本发明涉及用于治疗阴道干燥和缺乏润滑的组合物，其包含：泊洛沙姆组分; 磷脂成分; 可选的油成分; 和非水载体; 其中所述组合物基本上是无水的。另一方面，本发明涉及一种治疗阴道干燥的方法，包括向患有阴道干燥的患者施用上述组合物的步骤。

5. 发明申请

WO2004047554A1 MARINE LIPID COMPOSITIONS 审中-公开
标题翻译：海洋脂肪组合物
公开(公告)号：WO2004047554A1
公开(公告)日：2004-06-10
申请号：PCT/EP2003/013299
申请日：2003-11-26
申请人： PHARES PHARMACEUTICAL RESEARCH N.V. , LEIGH, Steve , KUNG, Elsa , VAN HOOGEVEST, Peter , TIEMESSEN, Henricus
发明人： LEIGH, Steve , KUNG, Elsa , VAN HOOGEVEST, Peter , TIEMESSEN, Henricus
IPC分类号： A23K1/18
CPC分类号： A23D9/013 , A23J7/00 , A23K20/147 , A23K40/10 , A23K40/30 , A23K50/80 , A23L33/115 , A23L33/12 , A23L33/17 , A23V2002/00 , C11B1/10 , C11B1/104 , Y02A40/818 , A23V2200/224 , A23V2250/192 , A23V2250/182 , A23V2250/05 , A23V2250/1842
摘要： There is described marine phospholipids (MPL) compositions suitable for human, aquaculture applications comprising a dry composition comprising nutritional components selected from the group consisting of marine phospholipids, marine proteins and amino acid blends obtainable by fluid extraction of a dried marine raw material. The compositions have low amounts of neutral lipids and particularly low amounts of cholesterol and cholesterol esters. They may be used either as such in powder form and for preparing purified MPL compositions by ethanol extraction. Both forms may be used as nutritional supplements, ingredients for functional foods and to optimise the delivery and containment of nutritional components in multicomponent fish feed compositions. There is further described a blend of the purified, ethanol extracted MPL compositions mixed with marine, vegetable, microbial or MCT oils to form liquid preparations for hard or soft gel encapsulation. There is further described MPL concentrates comprising purified and clearly defined phospholipid types dispersed in hydrophilic medium which are nutritionally essential in larvae feed. Still further there is described MPL compositions in unit dosage forms as supplements to supply highly bioavailable omega-3 fatty acids for human use, optionally with biologically active compounds.
摘要翻译：描述了适用于人，水产养殖应用的海洋磷脂（MPL）组合物，其包含干组合物，其包含选自海洋磷脂，海洋蛋白质和通过干燥的海洋原料的流体萃取获得的氨基酸混合物的营养成分。组合物具有低量的中性脂质，特别是低量的胆固醇和胆固醇酯。它们可以以粉末形式使用，也可以通过乙醇提取制备纯化的MPL组合物。两种形式可以用作营养补充剂，功能食品的成分，并优化多组分鱼饲料组合物中营养成分的输送和遏制。进一步描述了与海洋，植物，微生物或MCT油混合的纯化的乙醇提取的MPL组合物的混合物，以形成用于硬或软凝胶包封的液体制剂。进一步描述了MPL浓缩物，其包含分散在亲水介质中的纯化和明确定义的磷脂类型，其在幼虫饲料中是营养必需的。此外，还描述了单位剂型中的MPL组合物作为补充剂，为人类提供高度生物可利用的ω-3脂肪酸，任选地具有生物活性化合物。

6. 发明申请

WO2012085171A2 PHARMACEUTICAL COMPOSITIONS OF PYRIDINIUM AND QUINOLINIUM DERIVATIVES 审中-公开
标题翻译：吡啶和喹啉衍生物的药物组合物
公开(公告)号：WO2012085171A2
公开(公告)日：2012-06-28
申请号：PCT/EP2011/073722
申请日：2011-12-22
申请人： TRASLATIONAL CANCER DRUGS PHARMA, S.L. , PALACIOS IZQUIERDO, Beatriz , VAN HOOGEVEST, Peter , L.S. LEIGH, Mathew
发明人： PALACIOS IZQUIERDO, Beatriz , VAN HOOGEVEST, Peter , L.S. LEIGH, Mathew
IPC分类号： A61K9/127 , A61K47/48 , A61K9/00 , A61K31/4425 , A61K31/4706 , A61P31/10 , A61P31/12 , A61P33/00 , A61P35/00
CPC分类号： A61K47/40 , A61K9/0019 , A61K9/08 , A61K9/127 , A61K31/4425 , A61K31/4706 , A61K47/6951 , B82Y5/00 , C07D213/74 , C07D215/44
摘要： The present invention relates to pharmaceutical compositions comprising a compound of formula (I) and a cyclodextrin or a liposome, to the process of preparing said compositions and their use for antitumor, antiviral, antiparasitic and antifungal treatment.
摘要翻译：本发明涉及包含式（I）化合物和环糊精或脂质体的药物组合物，涉及制备所述组合物的方法及其用于抗肿瘤，抗病毒，抗寄生虫和抗真菌治疗的用途。

7. 发明申请

WO2003010330A3 TEST SYSTEM AND METHOD SUITABLE FOR SELECTING TEST MATERIALS AND FORMULATIONS 审中-公开
公开(公告)号：WO2003010330A3
公开(公告)日：2003-02-06
申请号：PCT/EP2002/008215
申请日：2002-07-23
申请人： PHARES PHARMACEUTICAL RESEARCH N.V. , LEIGH, Steve , LEIGH, Mathew, Louis, Steven , VAN HOOGEVEST, Peter , TIEMESSEN, Henricus
发明人： LEIGH, Steve , LEIGH, Mathew, Louis, Steven , VAN HOOGEVEST, Peter , TIEMESSEN, Henricus
IPC分类号： G01N33/50
摘要： The present invention provides a test system and a method for screening lipophilic and amphipathic materials with low water solubility. It generally relates to membrane lipid suspensions or dispersions employed as a test system for obtaining desired physico-chemical and biological information relating to the interaction of materials with membrane lipids in early screens in discovery. It serves as a selection method for derivatives of a test material for optimal membrane affinity and membrane permeation and thereby predict the potential for absorption in vivo. Furthermore, it may be used in later screening in formulation development, to select a carrier for a test material or derivative to enable the highest drug load. The data obtained by using the invention in primary screening provide key information on physico-chemical properties early on which may affect drug absorption and may be more predictive than log-octanol determinations. Compared to other screening methods which utilise cell models such as liposomes and cell lines, Transmembrane Screen (TS) is a versatile miniature tool that requires minimal amounts of test substances. It is adaptable, practical, cost effective and may be used routinely in high throughput screening.

8. 发明申请

WO2002080883A2 METHOD AND COMPOSITION FOR SOLUBILISING A BIOLOGICALLY ACTIVE COMPOUND WITH LOW WATER SOLUBILITY 审中-公开
标题翻译：用于溶解具有低水溶性的生物活性化合物的方法和组合物
公开(公告)号：WO2002080883A2
公开(公告)日：2002-10-17
申请号：PCT/EP2002/003371
申请日：2002-03-26
申请人： PHARES PHARMACEUTICAL RESEARCH N.V. , LEIGH, Steven , LEIGH, Mathew, Louis, Steven , VAN HOOGEVEST, Peter , TIEMESSEN, Henricus
发明人： LEIGH, Steven , LEIGH, Mathew, Louis, Steven , VAN HOOGEVEST, Peter , TIEMESSEN, Henricus
IPC分类号： A61K9/127
CPC分类号： A61K9/1075 , A61K9/1278
摘要： Compositions for forming molecular associates with lipophilic compounds and an improved method of loading lipophilic biologically active compounds into previously formed, aqueous suspensions of lipid particles. A preferred embodiment for injection purposes comprise lipid particles having sizes below 1000 nm in diameter, in a vial or other suitable container are described. The method involves mixing a lipophilic compound either in solution or as an amorphous, preferably lyophilised powder in a first container with an aqueous suspension of lipid particles contained in a second container to form molecular associates. Only minimum agitation is required. The entire procedure may be carried out instantly in situ, in sealed sterile units just prior to use in the hospital ward or by the bedside.
摘要翻译：用于与亲脂性化合物形成分子缔合物的组合物和将亲脂性生物活性化合物加载到先前形成的脂质颗粒水悬浮液中的改进方法。用于注射目的的优选实施方案包括直径小于1000nm，在小瓶或其它合适的容器中的脂质颗粒。该方法包括在第一容器中的溶液或无定形，优选冻干的粉末中混合亲脂性化合物与第二容器中含有的脂质颗粒的水性悬浮液以形成分子缔合物。只需要最小的搅动。整个程序可以在即将在医院病房或床边使用前的密封无菌单元中立即进行。

9. 发明申请

WO2007020057A1 CRYSTAL FORMS OF ASTAXANTHIN 审中-公开
标题翻译：阿司匹林的晶体形式
公开(公告)号：WO2007020057A1
公开(公告)日：2007-02-22
申请号：PCT/EP2006/008047
申请日：2006-08-15
申请人： PHARES PHARMACEUTICAL RESEARCH N.V. , LEIGH, Mathew, Louis, Steven , VAN HOOGEVEST, Peter , LEIGH, Steve
发明人： LEIGH, Mathew, Louis, Steven , VAN HOOGEVEST, Peter , LEIGH, Steve
IPC分类号： C07C49/653 , A23L1/275
CPC分类号： C07C403/24
摘要： This invention describes previously undisclosed mixtures of specific crystal forms of astaxanthin and the individual crystal forms designated crystal Form I and II together with methods for preparing said crystal Forms. Methods for preparing nutritional dosage forms comprising said novel astaxanthin crystal forms for the life science industry are also disclosed.
摘要翻译：本发明描述了以前未公开的虾青素的特定晶体形式的混合物，以及指定为晶型I和II的单独结晶形式以及制备所述晶形的方法。还公开了包含用于生命科学工业的所述新型虾青素晶体形式的营养剂型的方法。

10. 发明申请

WO2003042392A1 STANDARDISED PHOSPHOLIPID MIXTURES 审中-公开
标题翻译：标准化磷酸盐混合物
公开(公告)号：WO2003042392A1
公开(公告)日：2003-05-22
申请号：PCT/EP2002/012817
申请日：2002-11-15
申请人： PHARES PHARMACEUTICAL RESEARCH N.V. , LEIGH, Steve , LEIGH, Mathew, Louis, Steven , VAN HOOGEVEST, Peter , TIEMESSEN, Henricus
发明人： LEIGH, Steve , LEIGH, Mathew, Louis, Steven , VAN HOOGEVEST, Peter , TIEMESSEN, Henricus
IPC分类号： C12P7/62
CPC分类号： A23J7/00 , C11C3/12 , C12P7/6481 , C12P9/00 , C12P13/06
摘要： A standardised and optionally hydrogenated phospholipid composition comprising a phospholipase modified and the corresponding unmodified phospholipid and optionally other components obtainable by a method comprising: i) Modification of a phospholipid comprising at least 10% PC or 10% MAPC by enzyme treatment with phospholipase; ii) Purification of the enzyme modified mixture; iii) Addition of unmodified phospholipid with a minimum of 40% w/w PC or another diacylphospholipid to said enzyme modified and purified mixture to reach the desired target amount of the modified phospholipid. An enzyme modified composition comprising up to 85 wt % of mono acyl phosphatidylcho-line and 14 wt % of phosphatidylcholine before back blending is also described. The in-vention also describes a method of preparing said compositions.
摘要翻译：一种标准化和任选氢化的磷脂组合物，其包含修饰的磷脂酶和相应的未修饰的磷脂以及任选的其它可通过以下方法获得的组分：i）通过用磷脂酶酶处理来修饰包含至少10％PC或10％MAPC的磷脂; ii）酶改性混合物的纯化; iii）向所述酶修饰和纯化的混合物中加入至少40％w / w PC或另一种二酰基磷脂的未修饰磷脂，以达到所需目标量的修饰的磷脂。还描述了在回混之前包含高达85重量％的单酰基磷脂酰胆碱和14重量％的磷脂酰胆碱的酶修饰组合物。本发明还描述了制备所述组合物的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式